TABLE 2 ] .
Clinical Characteristics at Enrollment for All Patients and by Prostacyclin History
| Characteristics | All Patients (N = 336) | Parenteral-Naive (n = 147)a | Parenteral-Transitioned (n = 189)b |
| Specialty of diagnosing physician | |||
| Pulmonologist | 222 (66.1) | 101 (68.7) | 121 (64.0) |
| Cardiologist | 96 (28.6) | 37 (25.2) | 59 (31.2) |
| Other | 18 (5.4) | 9 (6.1) | 9 (4.8) |
| PAH duration in y | 4.7 ± 4.9 | 3.1 ± 4.5 | 5.9 ± 4.9 |
| NYHA functional class at enrollment | |||
| Class I | 14 (4.2) | 2 (1.4) | 12 (6.3) |
| Class II | 85 (25.3) | 24 (16.3) | 61 (32.3) |
| Class III | 169 (50.3) | 93 (63.3) | 76 (40.2) |
| Class IV | 38 (11.3) | 23 (15.6) | 15 (7.9) |
| Unknown | 30 (8.9) | 5 (3.4) | 25 (13.2) |
| 6MWD, m, mean ± SD | 334.6 ± 128.0 | 308.2 ± 113.4 | 350.5 ± 133.8 |
| Hemodynamic parameters | |||
| RAP, mm Hg | n = 259 | n = 112 | n = 147 |
| 11.9 ± 7.0 | 13.6 ± 7.0 | 10.7 ± 6.7 | |
| mPAP, mm Hg | n = 275 | n = 123 | n = 152 |
| 52.9 ± 14.3 | 54.8 ± 13.1 | 51.4 ± 15.1 | |
| PCWP, mm Hg | n = 266 | n = 116 | n = 150 |
| 11.5 ± 5.6 | 12.0 ± 6.2 | 11.1 ± 5.2 | |
| Cardiac index, L/min/m2 | n = 242 | n = 105 | n = 137 |
| 2.5 ± 1.0 | 2.3 ± 0.8 | 2.7 ± 1.1 | |
| Svo2, % | n = 59 | n = 24 | n = 35 |
| 61.8 ± 11.8 | 60.9 ± 11.3 | 62.5 ± 12.2 | |
| PVRI, Wood units × m2 | n = 225 | n = 99 | n = 126 |
| 19.7 ± 12.3 | 21.7 ± 12.0 | 18.0 ± 12.4 | |
| Concomitant PAH medications, at RTS-Epo start | |||
| PDE5i without ERA | 82 (24.4) | 32 (21.8) | 50 (26.5) |
| ERA without PDE5i | 49 (14.6) | 21 (14.3) | 28 (14.8) |
| PDE5i + ERA | 81 (24.1) | 37 (25.2) | 44 (23.3) |
| Neither | 124 (36.9) | 57 (38.8) | 67 (35.4) |
| Initial dose of RTS-Epoc | n = 316 | n = 127 | n = 189 |
| Median | 16.0 | 2.0 | 29.0 |
Data are given as mean ± SD or No. (%). 6MWD = 6-min walk distance; ERA = endothelial receptor antagonist; mPAP = mean pulmonary arterial pressure; NYHA = New York Heart Association; PDE5i = type 5 phosphodiesterase inhibitor; PAH = pulmonary arterial hypertension; PCWP = pulmonary capillary wedge pressure; PVRI = pulmonary vascular resistance index (Wood units × m2); RAP = right arterial pressure; RTS-Epo = room temperature stable-epoprostenol; Svo2 = venous oxygen saturation.
Includes n = 119 patients who were prostacyclin-naive, n = 26 patients who transitioned from an inhaled prostacyclin, and n = 2 patients who transitioned from an oral prostacyclin at study entry.
Includes n = 180 patients who transitioned from epoprostenol and n = 9 patients who transitioned from treprostinil at study entry.
The initial dose at time of initiation of prolonged RTS-Epo, which may not be at enrollment.